Obesity prevalence among people living with HIV (HIV+) is rising. HIV and obesity are associated with atherosclerosis, which is mediated by inflammation. Both are pro-inflammatory states, but their combined effect on inflammation (measured by interleukin 6, IL-6), altered coagulation (D-dimer), and monocyte activation (soluble CD14, sCD14) is unknown. We hypothesized that HIV infection and obesity (BMI≥30 kg/m2) synergistically increase IL-6, sCD14 and D-dimer in the Veterans Aging Cohort Study Biomarker Cohort (VACS BC).
VACS is a prospective, observational longitudinal study of HIV+ and HIV uninfected (HIV–) participants. VACS BC is a subset of VACS participants who provided blood samples for research. VACS BC participants with BMI<18.5 kg/m2 (underweight, N=48) were excluded since they were too few to stratify by HIV status (N=4 underweight HIV–). Dependent variables were IL-6, sCD14, and D-dimer quartiles. BMI was categorized as 18.5-24, 25-29, and ≥30kg/m2. Covariates included demographics, smoking, diabetes, CVD, hypertension, lipids, liver and renal function, HCV and statin use. Unadjusted and fully adjusted logistic regression models were constructed.
We analyzed data on 1495 HIV+ (66% of whom had HIV-1 RNA<500 copies/mL) and 837 HIV– participants. The mean age was 53 years. The majority were African American (68%); half were current smokers (49%). Over a quarter were obese (27%) or had prevalent CVD (22%). HIV+ obese participants were more likely to have diabetes, dyslipidemia, statin use, and HCV, and less likely to smoke than HIV– non-obese participants (p≤0.05 for all). IL-6 showed a stepwise increase from HIV– non-obese, to HIV+ non-obese, to HIV– obese, to HIV+ obese. Elevated IL-6 was more prevalent in obese HIV+ than HIV– non-obese, which persisted after adjustment for potential confounders (adjusted odds ratio, aOR [95% confidence interval, CI]: 1.69 (1.13-2.51); Table). The inverse was true for sCD14 (aOR (95% CI): 0.43 (0.27-0.66); Table). No significant differences were seen for D-dimer.
HIV-obesity comorbidity is associated with higher prevalence of elevated IL-6, lower prevalence of elevated sCD14 and no significant difference in D-dimer. These findings are clinically significant as all three biomarkers are associated with mortality. Future studies should assess 1) whether other biomarkers of monocyte activation and altered coagulation show similar trends and 2) potential mechanisms for the unanticipated sCD14 and D-dimer findings.